Genesys Spine Reports Positive Multicentre Study Results for SIros SI Joint Fusion System
Prospective multicentre data show significant pain reduction, improved function and strong fusion outcomes with the SIros Lateral Sacroiliac Joint Fusion System.
Industrial talks | 09/02/2026 | By News Bureau
UK MHRA Updates Safety Information on Semaglutide Over Rare NAION Vision Risk
UK MHRA flags a very rare risk of NAION linked to semaglutide, urging patients to seek immediate medical attention for sudden changes in vision.
Industrial talks | 07/02/2026 | By News Bureau
Entod Pharmaceuticals Backs Global Push to Prevent Childhood Blindness at UK House of Lords
Entod Pharmaceuticals representatives participate in global discussions at the UK House of Lords to advance prevention-led strategies against childhood blindness, with a focus on ROP screening in India.
Industrial talks | 05/02/2026 | By News Bureau
Sanofi Announces Euro 1 Billion Share Buyback Programme for 2026
R&D-driven biopharma major Sanofi to repurchase shares worth up to Euro 1 billion between February and December 2026, reinforcing its capital allocation strategy and long-term growth outlook.
Industrial talks | 04/02/2026 | By News Bureau
The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.
Industrial talks | 04/02/2026 | By News Bureau
Union Budget Boosts Pharma with Biopharma Shakti with Outlay of INR 10,000 Crore
Union Finance Minister Nirmala Sitharaman unveiled multiple initiatives for pharma and life sciences in budget 2026–27, including Biopharma Shakti, NIPER expansion, CDSCO strengthening and new investments, to position India as a global biopharma hub.
Industrial talks | 01/02/2026 | By News Bureau | 164
Alvotech Reaches Global Settlement on Eylea Biosimilar
The settlement enables Alvotech and its partners to launch the biosimilar from January 1, 2026 in the UK and Canada, from May 1, 2026 in the EEA and other markets outside the US, and in Japan from May 2026 for select indications, expanding to all approved indications from November 1, 2026.
Industrial talks | 30/01/2026 | By News Bureau | 119
India's Pharma Industry Clocks INR 4.72 Lakh Crore Turnover in FY25: Economic Survey
India’s pharmaceutical industry delivered a strong performance in the financial year 2024–25, recording a total turnover of INR 4.72 lakh crore, according to the latest Economic Survey. The figures highlight the sector’s resilience and its growing role as a key contributor to India’s economy and global healthcare supply chain.
Industrial talks | 29/01/2026 | By Darshana | 127
Bayer to Showcase Low-Dose MRI Contrast Innovation at ECR 2026
Bayer brings next-generation contrast agents and smart radiology solutions to ECR 2026, spotlighting progress in low-dose MRI imaging and clinical innovation.
Industrial talks | 28/01/2026 | By News Bureau | 118
EU Trade Pact Set to Boost Indian Pharma and Medical Device Exports
The recently finalised India–European Union Free Trade Agreement (FTA) is expected to significantly expand opportunities for India’s pharmaceutical and medical technology sectors by opening access to a USD 572 billion European healthcare market, Union Health Minister J.P. Nadda said.
Industrial talks | 28/01/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy